Kazia Therapeutics (NASDAQ:KZIA) reported preclinical results showing its PI3K/mTOR inhibitor paxalisib produced antitumor activity when combined with standard therapies in HR+/HER2- breast cancer models.
RedHill Biopharma (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq from Ferring Pharmaceuticals in a transaction focused on expanding its gastrointestinal business.
Adicet Bio (NASDAQ:ACET) completed the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus with or without lupus nephritis.
AstraZeneca (NASDAQ:AZN) completed its exclusive license agreement with Dizal Pharmaceutical for worldwide rights to develop and commercialize ZEGFROVY (sunvozertinib), an oral EGFR inhibitor for patients with lung cancer.
MiniMed (NASDAQ:MMED) reported first quarter fiscal 2027 net sales of $843 million, increasing 16.6% year over year on a reported basis and 15.8% organically.
Novartis (NYSE:NVS) reported positive Phase 3 REMODEL-1 and REMODEL-2 trial results showing remibrutinib reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.
Natera (NASDAQ:NTRA) announced the publication of new data in Blood Neoplasia showing that its Signatera circulating tumor DNA test provided prognostic and predictive information for patients with newly diagnosed and relapsed or refractory lymphoma.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo received European Union approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
Cadrenal Therapeutics (NASDAQ:CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting regarding the planned Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.
Ensysce Biosciences (NASDAQ:ENSC) announced completion of enrollment in Part 3 of the PF614-MPAR-102 clinical study, evaluating its MPAR overdose-protection technology for opioid medicines.
Axsome Therapeutics (NASDAQ:AXSM) announced that the first patient has been dosed in SUMMIT, a Phase 3 trial evaluating AXS-05 for smoking cessation in adult smokers.
Karyopharm Therapeutics (NASDAQ:KPTI) submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for XPOVIO (selinexor) combined with ruxolitinib to treat patients with myelofibrosis.
